As a tumor glyco-biomarker, carcinoembryonic antigen (CEA) is an effective indicator of response to cancer therapy. CD BioGlyco has developed a variety of sensitive and effective CEA detection methods using advanced instrumentation platforms and expertise.

CEA

As one of the most common gastrointestinal cancers worldwide, gastric cancer kills millions of patients each year. The survival rate of gastric cancer is only 20-25%, which may be the result of advanced diagnosis to a certain degree. In addition to tumor node-metastasis (TNM) stage and treatment choices, there may be other factors that affect the prognosis of gastric cancer patients, such as genetic abnormalities and tumor behavior and differentiation. Therefore, the choice of treatment is of great importance for the prognosis of patients with gastric cancer.

In 1965, CEA was identified by Gold and Freedman and was observed to potentiate metastasis of colon carcinoma cells, its sialofucosylated glycoforms act as selectin ligands. CEA is produced in a high proportion of cancers in many other organs. CEA has a significant impact on tumor metastasis and may be associated with gastric cancer prognosis. CEA levels are elevated in gastric cancer patients, which is related to the survival of patients according to a systemic evaluation of serum markers for gastric cancer. Therefore, there is a need to develop a highly advanced technique for specific and sensitive CEA assays for clinical research and diagnosis.

Our Strategies

CD BioGlyco has developed ultra-sensitive, simple and reliable strategies for the detection of glyco-biomarker CEA. The strategies we provide include but are not limited to:

• We provide selective and sensitive analysis of CEA by a sandwich-type electrochemical aptasensor with electrocatalyst and nanocarrier (i.e. Pt/Au diaminonaphthalene (DN)-graphene).
• We have constructed and tested a sandwich-type electrochemical immunosensor for CEA detection. In this method, a ferrocene derivative is integrated into the sensor design to detect CEA in buffers and biological samples and gold nanoparticles were used to increase the conductivity of the sensing surfaces.
• We developed a simple method for CEA determination based on the binding of dsDNA-modeled copper nanoparticles (CuNPs) to an aptamer. The assay provides a sensitive and accurate determination of CEA and has been successfully used in biological samples.

What We Provide

• We combine highly sensitive immunoassay tools, such as automated chemiluminescent immunoassays, for accurate quantification of total CEA.
• For the intricate analysis of CEA glycosylation, we employ state-of-the-art mass spectrometry techniques, including high-resolution liquid chromatography-tandem mass spectrometry (LC-MS/MS), which allows for the precise identification and quantification of individual N-linked and O-linked glycan structures.
• This is complemented by sophisticated sample preparation methods, including affinity enrichment and enzymatic glycan release, optimized to handle the complex nature of biological samples and the high degree of CEA glycosylation. Our rigorous quality control measures throughout the analytical process guarantee reliable and reproducible results.

Workflow

Applications

• Our services can be used to study the fundamental role of CEA glycosylation in tumor cell proliferation, adhesion, migration, invasion, and immune evasion, contributing to a deeper understanding of cancer biology.
• Our service can be applied to study CEA glycosylation in these diverse tumor types, revealing unique glyco-signatures.
• Our CEA analysis can be used to identify novel glyco-biomarkers and specific CEA glycoforms.
• Our CEA analysis can be used to assess the impact of novel therapeutic agents on CEA levels and their glycosylation patterns.

Advantages of Us

• Unlike conventional CEA tests that only provide a quantitative number, our service delves into the specific glycosylation patterns of CEA. This allows for the detection of subtle yet significant changes in glycan structures.
• By employing advanced enrichment strategies and high-resolution MS, our service achieves superior sensitivity and specificity in detecting CEA and its glycoforms.
• We translate complex glycomics data into clear, actionable insights, helping you understand the implications of the observed CEA glycosylation changes for your specific research questions.

Publication Data

Frequently Asked Questions

Knowing the details of CEA is helpful for doctors to make personalized treatment according to tumor characteristics. CD BioGlyco has developed multiple strategies for the detection of glyco-biomarker CEA. If you have a demand for glyco-biomarker detection services, please contact us for further information.

Associated Services

To provide comprehensive support for your glyco-biomarker research, CD BioGlyco offers several complementary services that can further enhance your projects related to CEA and other glycoproteins: